Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  Rutgers, Marijn ^a   Saris, Daniël B F ^a   Dhert, Wouter J A ^a,b   Creemers, Laura B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; ONCOSTATIN M; OSTEOPROTEGERIN; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS CONDITIONED SERUM; CARTILAGE; CELL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; JOINT CAVITY; MALE; OSTEOARTHRITIS; PROTEIN SECRETION; PROTEOGLYCAN SYNTHESIS; SERUM; SYNOVIAL FLUID; SYNOVIAL FLUID LEVEL; UPREGULATION; ARTICULAR CARTILAGE; CELL CULTURE; CULTURE MEDIUM; DRUG ANTAGONISM; INTRAARTERIAL DRUG ADMINISTRATION; KNEE OSTEOARTHRITIS; METABOLISM;

ANTIRHEUMATIC AGENTS; CARTILAGE, ARTICULAR; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRA-ARTERIAL; OSTEOARTHRITIS, KNEE; PROTEOGLYCANS; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953281255     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3050     Document Type: Article

References (51)

1. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997, 24:365-371.
2. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004, S27-36. 10.1097/01.blo.0000144854.66565.8f, 15480070.
3. Stove J, Huch K, Gunther KP, Scharf HP. Interleukin-1beta induces different gene expression of stromelysin, aggrecan and tumor-necrosis-factor-stimulated gene 6 in human osteoarthritic chondrocytes in vitro. Pathobiology 2000, 68:144-149. 10.1159/000055915, 11174072.
4. Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res 2004, 427(suppl):S37-46. 10.1097/01.blo.0000144484.69656.e4, 15480072.
5. Smith RL, Allison AC, Schurman DJ. Induction of articular cartilage degradation by recombinant interleukin 1 alpha and 1 beta. Connect Tissue Res 1989, 18:307-316. 10.3109/03008208909019079, 2787228.
6. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39:237-246.
7. Martel-Pelletier J, McCollum R, DiBattista J, Faure MP, Chin JA, Fournier S, Sarfati M, Pelletier JP. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum 1992, 35:530-540. 10.1002/art.1780350507, 1533521.
8. Sadouk MB, Pelletier JP, Tardif G, Kiansa K, Cloutier JM, Martel-Pelletier J. Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. Lab Invest 1995, 73:347-355.
9. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, Pelletier JP. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996, 39:1535-1544. 10.1002/art.1780390914, 8814066.
10. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002, 9:12-20. 10.1038/sj.gt.3301608, 11850718.
11. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC, Martel-Pelletier J. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997, 40:1012-1019. 10.1002/art.1780400604, 9182910.
12. Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res 2003, 52:404-407. 10.1007/s00011-003-1197-1, 14520515.
13. Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 1994, 139:71-78. 10.1111/j.1600-065X.1994.tb00857.x, 7927414.
14. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007, 68:290-296. 10.2460/ajvr.68.3.290, 17331019.
15. Yang KG, Raijmakers NJ, van Arkel ER, Caron JJ, Rijk PC, Willems WJ, Zijl JA, Verbout AJ, Dhert WJ, Saris DB. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008, 16:498-505. 10.1016/j.joca.2007.07.008, 17825587.
16. Baltzer AW, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009, 17:152-60. 10.1016/j.joca.2008.06.014, 18674932.
17. Wehling P, Moser C, Frisbie D, McIlwraith CW, Kawcak CE, Krauspe R, Reinecke JA. Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs 2007, 21:323-332. 10.2165/00063030-200721050-00004, 17896838.
18. Bos PK, Verhaar JA, van Osch GJ. Age-related differences in articular cartilage wound healing: a potential role for transforming growth factor beta1 in adult cartilage repair. Adv Exp Med Biol 2006, 585:297-309. full_text, 17120792.
19. Mello MA, Tuan RS. Effects of TGF-beta1 and triiodothyronine on cartilage maturation: in vitro analysis using long-term high-density micromass cultures of chick embryonic limb mesenchymal cells. J Orthop Res 2006, 24:2095-2105. 10.1002/jor.20233, 16955422.
20. Malfait AM, Verbruggen G, Veys EM, Lambert J, De Ridder L, Cornelissen M. Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose. J Rheumatol 1994, 21:314-320.
21. Westacott CI, Barakat AF, Wood L, Perry MJ, Neison P, Bisbinas I, Armstrong L, Millar AB, Elson CJ. Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis. Osteoarthritis Cartilage 2000, 8:213-221. 10.1053/joca.1999.0292, 10806049.
22. Flannery CR, Little CB, Hughes CE, Curtis CL, Caterson B, Jones SA. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 2000, 19:549-553. 10.1016/S0945-053X(00)00111-6, 11068209.
23. Henrotin YE, De Groote DD, Labasse AH, Gaspar SE, Zheng SX, Geenen VG, Reginster JY. Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis Cartilage 1996, 4:163-173. 10.1016/S1063-4584(96)80012-4, 8895217.
24. de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, Dang W, Zurawski G, de Vries JE. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993, 151:6370-6381.
25. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309. 10.1038/46303, 10580503.
26. Shimizu S, Asou Y, Itoh S, Chung UI, Kawaguchi H, Shinomiya K, Muneta T. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 2007, 56:3358-3365. 10.1002/art.22941, 17907189.
27. Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, Clark IM, Cawston TE. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002, 46:961-967. 10.1002/art.10212, 11953973.
28. Henrotin YE, Zheng SX, Labasse AH, Deby GP, Crielaard JM, Reginster JY. Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis Cartilage 2000, 8:474-482. 10.1053/joca.1999.0323, 11069732.
29. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990, 85:1694-1697. 10.1172/JCI114622, 296623, 2139669.
30. Altman RD. Criteria for the classification of osteoarthritis of the knee and hip. Scand J Rheumatol Suppl 1987, 65:31-39. 10.3109/03009748709102175, 3317807.
31. Vuolteenaho K, Moilanen T, Hamalainen M, Moilanen E. Effects of TNFalpha-antagonists on nitric oxide production in human cartilage. Osteoarthritis Cartilage 2002, 10:327-332. 10.1053/joca.2002.0521, 11950256.
32. Whiteman P. The quantitative measurement of Alcian Blue-glycosaminoglycan complexes. Biochem J 1973, 131:343-350. 1177474, 4269149.
33. Kim YJ, Sah RL, Doong JY, Grodzinsky AJ. Fluorometric assay of DNA in cartilage explants using Hoechst 33258. Anal Biochem 1988, 174:168-176. 10.1016/0003-2697(88)90532-5, 2464289.
34. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003, 10:133-139. 145264, 12522051.
35. de Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 2005, 300:124-135. 10.1016/j.jim.2005.03.009, 15896801.
36. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808. 10.1056/NEJMoa052771, 16495392.
37. Juni P, Reichenbach S, Trelle S, Tschannen B, Wandel S, Jordi B, Zullig M, Guetg R, Jorg Hauselmann H, Schwarz H, Theiler R, Ziswiler HR, Dieppe PA, Villiger PM, Egger M. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum 2007, 56:3610-3619. 10.1002/art.23026, 17968921.
38. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009, 10:52. 10.1186/1471-2172-10-52, 2761376, 19785746.
39. Suga M, Keshavjee S, Liu M. Instability of cytokines at body temperature. J Heart Lung Transplant 2005, 24:504-505. 10.1016/j.healun.2003.11.403, 15797758.
40. Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989, 75:306-310. 1542106, 2784740.
41. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996, 39:797-809. 10.1002/art.1780390513, 8639177.
42. Fernandes J, Tardif G, Martel-Pelletier J, Lascau-Coman V, Dupuis M, Moldovan F, Sheppard M, Krishnan BR, Pelletier JP. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999, 154:1159-1169. 1866546, 10233854.
43. Richette P, Francois M, Vicaut E, Fitting C, Bardin T, Corvol M, Savouret JF, Rannou F. A high interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis. J Rheumatol 2008, 35:1650-1654.
44. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Kiefer P, Zhou L, Bevirt T, Appleton B. Results from a double blind, placebo-controlled, multicenter trial of a single intra-articular injection of anakinra (kineret (R)) in patients with osteoarthritis of the knee. Arthritis and Rheumatism 2005, 52:S507-S507.
45. Schlaak JF, Pfers I, Meyer Zum Buschenfelde KH, Marker-Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol 1996, 14:155-162.
46. Vignon E, Balblanc JC, Mathieu P, Louisot P, Richard M. Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids. Osteoarthritis Cartilage 1993, 1:115-120. 10.1016/S1063-4584(05)80026-3, 8886087.
47. Huch K, Wilbrink B, Flechtenmacher J, Koepp HE, Aydelotte MB, Sampath TK, Kuettner KE, Mollenhauer J, Thonar EJ. Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, prostaglandin E2, and interleukin-1 receptor antagonist by human articular chondrocytes cultured in the presence of interleukin-1beta. Arthritis Rheum 1997, 40:2157-2161. 10.1002/art.1780401209, 9416852.
48. Shakibaei M, John T, Seifarth C, Mobasheri A. Resveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. Ann N Y Acad Sci 2007, 1095:554-563. 10.1196/annals.1397.060, 17404069.
49. Lippiello L. Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress. Osteoarthritis Cartilage 2003, 11:335-342. 10.1016/S1063-4584(03)00026-8, 12744939.
50. Durigova M, Roughley PJ, Mort JS. Mechanism of proteoglycan aggregate degradation in cartilage stimulated with oncostatin M. Osteoarthritis Cartilage 2008, 16:98-104. 10.1016/j.joca.2007.05.002, 17574450.
51. Baltzer AW, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009, 17:152-160. 10.1016/j.joca.2008.06.014, 18674932.